GlassScriptPhysician profile
William C Campbell
NPI 1023287745
$9,179.39
in general payments reported to CMS, 2019-2025
48 companies · $1,523 in 2025
The $1,523 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,199 · 2020: $1,069 · 2021: $1,040 · 2022: $1,518 · 2023: $1,294 · 2024: $1,535 · 2025: $1,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,352.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,379.06 | 2021-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $1,194.78 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $769.99 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $711.34 | 2019-2025 | |
| Lilly USA, LLC | $672.44 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $548.83 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $487.74 | 2021-2024 | |
| Orexo US, INC. | $372.06 | 2019-2025 | Zubsolv |
| Indivior INC. | $329.70 | 2019-2025 | Sublocade |
| Almatica Pharma LLC | $305.38 | 2021-2025 | Loreev Xr, Gralise |
| Otsuka America Pharmaceutical, INC. | $220.63 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $193.20 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.34 | 2020-2025 | Xifaxan, Relistor |
| Collegium Pharmaceutical, INC. | $163.71 | 2019-2025 | Xtampza, Belbuca |
| Radius Health, INC. | $159.35 | 2025 | Tymlos |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.